NanoString Technologies gained in morning trading on Wednesday, a day after the provider of life science tools said Humana has issued a positive coverage decision for the Prosigna Breast Cancer Gene Signature Assay.
Shares were trading up 2.2% to $18.44 after touching $18.60 earlier in the session. Humana and its more than 13 million members join other payors now covering Prosigna, collectively representing more than 175 million covered lives throughout the United States.
NanoString said the decision is in line with updated ASCO guidelines released in February of 2016, wherein Prosigna is considered medically necessary to assess the necessity of adjuvant chemotherapy in ER-positive, HER2-negative, node-negative breast cancer patients, when adjuvant chemotherapy is not precluded due to any other factor.
“Coverage by Humana is another important milestone in making our Prosigna test available to all indicated patients,” NanoString CEO Brad Gray was quoted in the statement as saying.